We are live on
!
Find out more
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
18 hedge funds and large institutions have $348K invested in ImmunoCellular Therapeutics, Ltd. in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
57% more capital invested
Capital invested by funds: $221K → $348K (+$127K)
13% more funds holding
Funds holding: 16 → 18 (+2)
Holders
18
Holders Change
+2
Holders Change %
+12.5%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$267K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$21.4K |
| 3 |
VF
Virtu Financial
New York
|
+$15.3K |
| 4 |
Bank of New York Mellon
New York
|
+$12.2K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$11.7K |
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$300 |